Quick Answer
Metagenomi Therapeutics, Inc. reported Diluted EPS of $2.36 per share (loss) for fiscal year 2025.
Metagenomi Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.36 | +0.0% |
| 2024 | -$2.36 | +88.2% |
| 2023 | -$20.05 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.55 | -7.8% | -1.9% |
| June 30, 2025 | -$0.54 | -86.2% | +20.6% |
| March 31, 2025 | -$0.68 | +42.9% | -33.3% |
| September 30, 2024 | -$0.51 | +91.2% | -75.9% |
| June 30, 2024 | -$0.29 | +92.4% | +75.6% |
| March 31, 2024 | -$1.19 | +74.9% | +79.6% |
| September 30, 2023 | -$5.82 | — | -52.4% |
| June 30, 2023 | -$3.82 | — | +19.4% |
- Metagenomi Therapeutics, Inc. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s diluted eps has grown by 88.2% (from $20.05 per share (loss) to $2.36 per share (loss)).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: